Molbio Diagnostics Targets ₹940 Crore in IPO to Fund Expansion

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is poised to launch an initial public offering (IPO) aimed at raising ₹940 crore. This strategic move is designed to bolster the company's capital expenditures and reduce the promoter group's stake from 46.6% to 43%, signaling a significant shift in its ownership structure.

IPO Structure and Financial Goals

The IPO comprises a fresh issue of shares amounting to ₹200 crore, alongside an offer for sale that is expected to generate ₹740 crore. This dual approach is intended to support Molbio's ongoing expansion efforts, particularly in enhancing its manufacturing capabilities and broadening its market reach.

With six manufacturing sites, Molbio caters to over 90 countries, focusing on diagnostic solutions for both infectious and non-communicable diseases. The company's flagship product, the Truenat platform, offers rapid diagnostic results within an hour, making it a valuable tool in resource-limited settings. This platform supports over 30 diseases through 43 diagnostic assays.

Revenue Growth and Market Position

Molbio has reported robust financial performance, with revenue from operations increasing by 31.5% annually to ₹1,445.7 crore between FY24 and FY26. During the same period, net profit surged by 40.2% to ₹164.1 crore. The company's EBITDA rose 33.2% to ₹328.2 crore, with margins improving to 22.6% in FY26 from 22% in FY24.

Approximately 74% of Molbio's revenue is derived from the sale of test kits, with 70% attributed to tuberculosis diagnostic kits. This concentration underscores the company's reliance on a few key products and clients, as over half its revenue comes from top customers, including government and international aid agencies.

Valuation and Investor Considerations

The IPO places Molbio's valuation at a price-earnings (P/E) multiple of up to 57, which is competitive within the healthcare diagnostics and medical device sector. While Molbio lacks a directly comparable peer in India, companies like Poly Medicure, Dr. Lal PathLabs, and Metropolis Healthcare trade at P/E multiples ranging from 54 to 81.

Investors with a high-risk appetite may find Molbio's IPO attractive, given its growth trajectory and the expanding global demand for diagnostic solutions. However, the company’s revenue concentration and the competitive landscape pose potential risks.

As Molbio Diagnostics prepares to tap into public markets, its ability to sustain growth and diversify its product offerings will be closely watched by investors and industry analysts alike.